Accelerating Drug Development - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Accelerating Drug Development
FDA's new safety program, Critical Path Initiative, and user-fee proposal seek to reinvigorate pharmaceutical R&D.

Pharmaceutical Technology

Modernizing manufacturing

This campaign includes several projects designed to "move manufacturing into the 21st century" by developing standards for laboratory and production analytical methods. To encourage the adoption of process analytical technology, for example, FDA is partnering with pharmaceutical and instrument manufacturers to test validation reference systems. The aim is to establish specifications for imaging methods such as near-infrared, mid-infrared, Raman chemical imaging (RCI), and terahertz technologies. Standards that ensure proper calibration and instrument qualification would lead to FDA guidance for adopting such methods in continuous quality-controlled manufacturing processes.

Other collaborations with industry and academia aim to ensure that policy development, training, and regulatory practices are consistent with state-of-the-art science. FDA has signed Cooperative Research and Development Agreements (CRADAs) with Pfizer and Novartis to expand understanding, and ultimately control, of material transformation. Another CRADA with Conformia Software seeks better understanding of the challenges and bottlenecks that influence pharmaceutical development. Additional PAT-related research ventures involve FDA and Duquesne University, the Center for Pharmaceutical Processing Research, the National Institute for Pharmaceutical Technology and Education, and the Engineering Research Center for Structured Organic Composites.

New dosage forms. FDA also is encouraging new standards and methods for novel drug dosage forms to expand options for drug delivery. One project aims to refine and validate the use of RCI to establish scientific standards for chemical identity, particle size, and distribution characteristics of active pharmaceutical ingredients in aqueous nasal-spray suspensions. If successful, this approach could be applied to dry-powder and metered-dose inhalers. Another FDA–industry collaboration is developing methods to assess the adhesive properties and permeation of various transdermal products. The objective is to compare drug diffusion and skin permeation through different in vitro methods, an exercise that eventually could lead to American Society for Testing and Materials standards and agency guidance for these products.

FDA also is working to characterize liposomal drug products for their encapsulation efficiency, leakage, and particle size. The project involves testing performance under various physiologic stress factors, with an eye to developing in vitro cell-line bioassay methods to assess changes in liposomes under different conditions.

Laboratory standards. A high-profile project is to establish standards for multi-color flow-cytometry measurements in various laboratories and across instrument platforms. Because flow-cytometry data are important for developing many medical products, FDA is collaborating with instrument makers and the National Institute of Standards and Technology (NIST), the Centers for Disease Control and Prevention, the Environmental Protection Agency, the NIH, the International Society of Cytometry, and the Clinical Cytometry Society to develop, test, and validate standards that will ensure comparability of such measurements.

Similarly, a Microarray Quality Control Project involving scientists at federal agencies, academia, and pharmaceutical companies is testing the reliability of microarray tools in measuring gene expression. Initial tests showed that these data can be reproducibly measured across multiple drugs and laboratories.

Biotechnology improvements. Several projects seek to modernize vaccine production. FDA is supporting research to shift influenza-vaccine production from egg-based systems to cell-culture substrates and to establish libraries of possible pandemic influenza virus strains to help manufacturers test new vaccines for potency and efficacy more quickly. These projects can support efforts to produce safe and low-cost vaccines for developing countries such as new vaccines for meningitis and tuberculosis. FDA scientists also are collaborating on research to evaluate the efficacy of mumps vaccines and to develop biomarkers to evaluate the stability and safety of future vaccines for malaria and leishmaniasis.

Related efforts aim to improve the safety of biotechnology manufacturing processes, including those used in vaccine production. An FDA collaboration with the National Institutes of Allergy and Infectious Diseases is examining methods for detecting infectious contaminants in cell cultures and whether such contaminants increase the risk of causing tumors. Additional projects seek to improve the characterization of complex biological products. FDA is exploring how to adapt high-tech imaging methods such as nuclear magnetic resonance spectroscopy to better characterize glycoprotein vaccines, allergen extracts, and other complex products. Similarly, a collaboration of FDA, NIH, and other partners is evaluating how well new microarray technologies and other tools can better predict the quality of cell substrates used to manufacture vaccines, protein drugs, and gene vectors. The discovery of specific gene-expression patterns or the identification of clusters of specific genes may help characterize cell substrates and serve as biomarkers of manufacturing quality.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here